Clinical implications of macrolide resistance in community-acquired respiratory tract infections

References

• Volturo GA, Low DE, Aghababian R. Managing acute lower respiratory tract infections in an era of antibacterial resistance. Am. J. Emergency Med.24(3), 329–342 (2006).
   PubMed Web of Science ®Google Scholar
• Woodwell DA, Cherry DK. National Ambulatory Medical Care Survey: 2002 Summary. no. 346. Hyattsville, Md: National Center for Health Statistics. Advance Data from Vital and Health Statistics. August 26 (2004).
   Google Scholar
• Gotfried MH. Macrolides for the treatment of chronic sinusitis, asthma, and COPD. Chest125(Suppl. 2), S52–S60 (2004).
   PubMedGoogle Scholar
• Tellier G, Chang JR, Asche CV, Lavin B, Stewart J, Sullivan SD. Comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days. Curr. Med. Res. Opin.20(5), 739–747 (2004). Erratum in: Curr. Med. Res. Opin.20(8), 1331 (2004).
   PubMed Web of Science ®Google Scholar
• Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. The cost of treating community-acquired pneumonia. Clin. Ther.20(4), 820–837 (1998).
   PubMed Web of Science ®Google Scholar
• File Jr. TM, Garau J, Blasi F et al. Guidelines in empiric antimicrobial prescribing in community-acquired pneumonia. Chest125(5), 1888–1901 (2004).
   PubMed Web of Science ®Google Scholar
• Gotfried MH. Comparison of bacteriological eradication of Streptococcus pneumoniae by clarithromycin and reports of increased antimicrobial resistance. Clin. Ther.22(1), 2–14 (2000).
   PubMed Web of Science ®Google Scholar
• Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. Treatment cost of acute exacerbations of chronic bronchitis. Clin. Ther.21(3), 576–591 (1999).
   PubMed Web of Science ®Google Scholar
• Anzueto A, Norris S. Clarithromycin in 2003; sustained efficacy and safety in the era of rising antibiotic resistance. Int. J. Antimicrob. Agents24(1), 1–17 (2004).
   PubMed Web of Science ®Google Scholar
• McCarty JM. Clarithromycin in the management of community-acquired pneumonia. Clin. Ther.22(3), 281–294, Discussion 265 (2000).
   PubMed Web of Science ®Google Scholar
• Nuermberger E, Bishai WR. The clinical significance of macrolide-resistant Streptococcus pneumoniae: it’s all relative. Clin. Infect. Dis.38(1), 99–103 (2004).
   PubMed Web of Science ®Google Scholar
• Wierzbowski AK, Hoban DJ, Hisanaga T, DeCorby M, Zhanel G. The use of macrolides in treatment of upper respiratory tract infections. Curr. Infect. Dis. Rep.7(3), 175–184 (2005).
   PubMedGoogle Scholar
• Mandell LA, Bartlett JG, Dowell SF, File TM, Musher DM, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin. Infect. Dis.37(11), 1405–1433 (2003).
   PubMed Web of Science ®Google Scholar
• Roberts MC, Sutcliffe J, Courvalin P, Jensen LB, Rood J, Seppala H. Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants. Antimicrob. Agents Chemother.43(12), 2823–2830 (1999).
   PubMed Web of Science ®Google Scholar
• Amsden GW. Advanced-generation macrolides: tissue-directed antibiotics. Int. J. Antimicrob. Agents.18(Suppl. 1), S11–S15 (2001).
   PubMed Web of Science ®Google Scholar
• Jain R, Danziger LH. The macrolide antibiotics: a pharmacokinetic and pharmacodynamic overview. Curr. Pharm. Des.10(25), 3045–3053 (2004).
   PubMed Web of Science ®Google Scholar
• Zuckerman JM. The newer macrolides: azithromycin and clarithromycin. Infect. Dis. Clin. North Am.14(2), 449–462 (2000).
   PubMed Web of Science ®Google Scholar
• Doern GV. Antimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumoniae in the United States. Clin. Infect. Dis.33(Suppl. 3), S187–S192 (2001).
   PubMed Web of Science ®Google Scholar
• Zhanel GG. Antibacterial drivers of resistance. Treat. Respir. Med.4(Suppl. 1), S13–S18 (2005).
   PubMedGoogle Scholar
• Doern GV, Richter SS, Miller A et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antibiotic classes? Clin. Infect. Dis.41, 139–148 (2005).
   PubMed Web of Science ®Google Scholar
• Patel KB, Xuan D, Tessier PR, Russomanno JH, Quintiliani R, Nightingale CH. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob. Agents Chemother.40(10), 2375–2379 (1996).
   PubMed Web of Science ®Google Scholar
• Gotfried MH, Danziger LH, Rodvold KA. Steady-state plasma and bronchopulmonary characteristics of clarithromycin extended-release tablets in normal healthy adult subjects. J. Antimicrob. Chemother.52(3), 450–456 (2003).
   PubMedGoogle Scholar
• Conte Jr. JE, Golden JA, Duncan S, McKenna E, Zurlinden E. Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin. Antimicrob. Agents. Chemother.39(2), 33–48 (1995).
   Google Scholar
• Rodvold KA, Gotfried MH, Danziger LH, Servi RJ. Intrapulmonary steady-state of clarithromycin and azithromycin in healthy adult volunteers. Antimicrob. Agents Chemother.41(6), 1399–1402 (1997).
   PubMed Web of Science ®Google Scholar
• Jorgensen JH, Maher LA, Howell AW. Activity of clarithromycin and its principal human metabolite against Haemophilus influenzae. Antimicrob. Agents Chemother.35(7), 1524–1526 (1991).
   PubMed Web of Science ®Google Scholar
• Kostadima E, Tsiodras S, Alexopoulos EI et al. Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma. Eur. Respir. J.23(5), 714–717 (2004).
   Google Scholar
• Bishai WR. Clinical significance of pneumococcal resistance and factors influencing outcomes. Treat. Resp. Med.4(Suppl. 1), 19–23 (2005).
   PubMedGoogle Scholar
• Rechtweg JS, Moinuddin R, Houser SM, Mamikoglu B, Corey JP. Quality of life in treatment of acute rhinosinusitis with clarithromycin and amoxicillin/clavulanate. Laryngoscope114(5), 806–810 (2004).
   PubMed Web of Science ®Google Scholar
• Tellier G, Niederman MS, Nusrat R, Patel M, Lavin B. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J. Antimicrob. Chemother.54(2), 515–523 (2004).
   PubMed Web of Science ®Google Scholar
• Khair OA, Andrews JM, Honeybourne D, Jevons G, Vacheron F, Wise R. Lung concentrations of telithromycin after oral dosing. J. Antimicrob. Chemother.47(6), 837–840 (2001).
   PubMed Web of Science ®Google Scholar
• Reinert RR, van der Linden M, Al-Lahham A. Molecular characterization of the first telithromycin-resistant Streptococcus pneumoniae isolate in Germany. Antimicrob. Agents Chemother.49(8), 3520–3522 (2005).
   PubMedGoogle Scholar
• Rantala M, Haanpera-Heikkinen M, Lindgren M, Seppala M, Houvinen P, Jalava J. Streptococcus pneumoniae isolates resistant to telithromycin. Antimicrob. Agents Chemother.50(5), 1855–1888 (2006).
   PubMed Web of Science ®Google Scholar
• Lonks JR, Garau J, Gomez L et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin. Infect. Dis.35(5), 556–564 (2003).
   Google Scholar
• Jacobs MR. In vivo veritas: in vitro macrolide resistance in systemic Streptococcus pneumoniae infections does result in clinical failure. Clin. Infect. Dis.35(5), 56–59 (2002).
   Google Scholar
• Rzeszutek M, Wierzbowski A, Hoban DJ, Conly J, Bishai W, Zhanel GG. A review of clinical failures associated with macrolide-resistant Streptococcus pneumoniae. Int. J. Antimicrob. Agents.24(2), 95–104 (2004).
   PubMedGoogle Scholar
• Daneman N, McGeer A, Green K, Low DE. Macrolide resistance in bacteremic pneumococcal disease: Implications for patient management. Clin. Infect. Dis.43(4), 432–438 (2006).
   PubMed Web of Science ®Google Scholar
• Hoban D, Waites K, Felmingham D. Antimicrobial susceptibility of community acquired respiratory tract pathogens in North America in 1999–2000: findings of the PROTEKT surveillance study. Diagn. Microbiol. Infect. Dis.45(4), 251–259 (2003).
   Google Scholar
• Doern GV, Brown SD. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000–2001. J. Int. Infect.48(1), 56–65 (2004).
   PubMed Web of Science ®Google Scholar
• Thornsberry C, Sahm DF, Kelly LJ et al. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST surveillance program, 1999–2000. Clin. Infect. Dis.34(Suppl. 1), S4–S16 (2002).
   PubMed Web of Science ®Google Scholar
• Jacobs MR, Felmingham D, Appelbaum PC, Grüneberg RN, The Alexander Project Group. The Alexander Project 1998–2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J. Antimicrob. Chemother.52(2), 229–246 (2003).
   PubMed Web of Science ®Google Scholar
• Washington JA, The Alexander Project Group. A multi-center study of the antimicrobial susceptibility of community-acquired lower respiratory tract pathogens in the United States, 1992–1994. The Alexander project. Diagn. Microbiol. Infect. Dis.25(4), 183–190 (1996).
   PubMedGoogle Scholar
• Doern GV, Heilmann KP, Huynh HK, Rhomberg PR, Coffman SL, Brueggemann AB. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 19992000, including a comparison of resistance rates since 1994–1995. Antimicrob. Agents. Chemother.45(6), 1721–1729 (2001).
   PubMed Web of Science ®Google Scholar
• Lynch JP, Martinez FJ. Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia. Clin. Infect. Dis.34(Suppl. 1), S27–S46 (2002).
   PubMedGoogle Scholar
• Bishai W. The in-vivo in vitro paradox in pneumococcal respiratory tract infections. J. Antimicrob. Chemother.49(3), 433–436 (2002).
   PubMed Web of Science ®Google Scholar
• File TM. Solution to the problem of bacterial resistance. Treat Respir. Med.4(Suppl 1), 25–30 (2005).
   PubMedGoogle Scholar
• Zhanel GG, DeCorby M, Noreddin A et al. Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations. J. Antimicrob. Chemother.52(1), 83–88 (2003).
   PubMed Web of Science ®Google Scholar
• Ambrose PG. Antimicrobial susceptibility breakpoints. PK-PD and susceptibility breakpoints. Treat. Resp. Med.4(Suppl. 1), S5–S11 (2005).
   PubMedGoogle Scholar
• Lonks JR, Goldman DA. Telithromycin: a ketolide antibiotic for treatment of respiratory tract infections. Clin. Infect. Dis.40(11), 1657–1664 (2005).
   PubMed Web of Science ®Google Scholar
• Al-Tatari H, Abdel-Haq N, Chearskul P, Asmar B. Antibiotics for treatment of resistant Gram-positive coccal infections. Indian J. Pediatr.73(4), 323–334 (2006).
   PubMedGoogle Scholar
• Hoban H, Felmingham D. The PROTEKT surveillance study: antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections. J. Antimicrob. Chemother.50(Suppl. S1), S49–S59 (2002).
   PubMed Web of Science ®Google Scholar